Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Roche to acquire Telavant for $7.1b.
View:
Post by fox7mf on Oct 23, 2023 9:23am

Roche to acquire Telavant for $7.1b.

Telavant holdings is currently owned by PFE and is having promising results treating crohns. Where's Oncy's deal? We wait...I guess.
Comment by Noteable on Oct 23, 2023 9:43am
Roche to acquire Telavant Holdings experimental IBD drug known as RVT-3101 for $7.1 billion.  Roche said that it would buy Telavant Holdings, a vehicle in which Roivant and Pfizer have placed the rights to develop, manufacture and commercialize the experimental drug known as RVT-3101 in the United States and Japan. https://www.reuters.com/markets/deals/roche-buys-telavant ...more  
Comment by Noteable on Oct 23, 2023 12:21pm
https://www.thestreet.com/investing/stocks/roivant-surges-as-ramaswamy-found-firm-reaches-7-1-billion-roche-deal
Comment by Noteable on Oct 23, 2023 12:29pm
June 2023 -    Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period https://investor.roivant.com/news-releases/news-release-details/roivant-reports-chronic-period-data-rvt-3101-tuscany-2-phase-2b
Comment by Noteable on Oct 23, 2023 12:38pm
“.... results were further enhanced in the roughly 60% of patients selected by a prospectively defined biomarker which had been identified in the earlier Phase 2a TUSCANY study. ”
Comment by Noteable on Oct 23, 2023 12:52pm
On the strength of biomarker data in Riovants Phase2b study , Roche is very likely looking towards filing an Accelerated Approval with the FDA for Telavant.
Comment by 13X2413 on Oct 23, 2023 9:44am
Oncy's deal? Apparently todays news wasn't highly thought of. Why would there be interest from anybody if everything they release knocks the share price further down.  To me, it looks like ONC doesn't have much to offer. Price action=public sentiment. 
Comment by canadafan on Oct 23, 2023 12:15pm
There is a strong underlying group of shorters & bashers working hard to suppress any good news out in Onc. Don't believe me! Twice in the past week. Two of my posts over on another chat site have been pulled down. neither attacked anyone. I don't do that. Regarding SP & investor sentiment, you are 100% correct, with some broader ( time & understanding) intellect. 1. Onc is ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities